Literature DB >> 22751127

Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops.

J A G C Laisney1, T D Mueller, M Schartl, S Meierjohann.   

Abstract

The epidermal growth factor (EGF) receptor (EGFR) has a key role in normal embryonic development, adult tissue homeostasis and many pathological processes, in particular tumour formation. Aberrant EGFR activation occurs in many cancer types, and inhibition of this receptor is a promising anti-tumour strategy. Besides overexpression of the wild-type receptor, mutated oncogenic EGFR variants are often associated with malignant transformation. In human non-small-cell lung cancers, kinase mutants of the EGFR are rather common. Human glioblastoma often express the truncated EGFRvIII version as well as other dimerized and permanently activated mutants of the receptor, which are considered as tumour drivers. Similarly, the mutated and dimerized EGFR variant Xiphophorus melanoma receptor kinase (Xmrk) is causative for the development of malignant pigment cell tumours in medaka and Xiphophorus melanoma models. It is generally believed that oncogenic receptors that are active due to dimerizing mutations are ligand independent. Here, we show that different EGFR variants from fish and human efficiently induce autocrine loops by inducing EGFR ligands such as amphiregulin and HB-EGF. Importantly, the pre-dimerized oncogenic EGFR versions Xmrk from Xiphophorus and human EGFR(C600F), though already active in absence of ligands, respond to ligand stimulation with enhanced oncogenic signalling. In summary, our data show that autocrine or paracrine loops are still acting on pre-dimerized oncogenic EGFRs and contribute to their pro-tumorigenic signalling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751127     DOI: 10.1038/onc.2012.267

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer.

Authors:  Daniel C Bennett; Jonathan Charest; Katrina Sebolt; Mark Lehrman; Alnawaz Rehemtulla; Joseph N Contessa
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

2.  The genome of the platyfish, Xiphophorus maculatus, provides insights into evolutionary adaptation and several complex traits.

Authors:  Manfred Schartl; Ronald B Walter; Yingjia Shen; Tzintzuni Garcia; Julian Catchen; Angel Amores; Ingo Braasch; Domitille Chalopin; Jean-Nicolas Volff; Klaus-Peter Lesch; Angelo Bisazza; Pat Minx; LaDeana Hillier; Richard K Wilson; Susan Fuerstenberg; Jeffrey Boore; Steve Searle; John H Postlethwait; Wesley C Warren
Journal:  Nat Genet       Date:  2013-03-31       Impact factor: 38.330

Review 3.  Hypoxia-independent drivers of melanoma angiogenesis.

Authors:  Svenja Meierjohann
Journal:  Front Oncol       Date:  2015-05-05       Impact factor: 6.244

4.  Whole Body Melanoma Transcriptome Response in Medaka.

Authors:  Manfred Schartl; Yingjia Shen; Katja Maurus; Ron Walter; Chad Tomlinson; Richard K Wilson; John Postlethwait; Wesley C Warren
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

5.  BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.

Authors:  Johannes Grimm; Anita Hufnagel; Marion Wobser; Andreas Borst; Sebastian Haferkamp; Roland Houben; Svenja Meierjohann
Journal:  Oncogenesis       Date:  2018-09-20       Impact factor: 7.485

6.  NRF2 Enables EGFR Signaling in Melanoma Cells.

Authors:  Julia Katharina Charlotte Kreß; Christina Jessen; André Marquardt; Anita Hufnagel; Svenja Meierjohann
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 7.  Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.

Authors:  Jerry D Monroe; Faiza Basheer; Yann Gibert
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

Review 8.  The role of proteases in regulating Eph/ephrin signaling.

Authors:  Lakmali Atapattu; Martin Lackmann; Peter W Janes
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

9.  The MAPK pathway as an apoptosis enhancer in melanoma.

Authors:  Johannes M Haydn; Anita Hufnagel; Johannes Grimm; Katja Maurus; Manfred Schartl; Svenja Meierjohann
Journal:  Oncotarget       Date:  2014-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.